Acadian Asset Management’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
Other funds holding PRLD
BBA
KCM
Acadian Asset Management's PRLD Position: Q3 2026 in Review
Acadian Asset Management increased its Prelude Therapeutics (PRLD) stake by 38% in Q3 2026, buying an estimated $1.14M and bringing the position to 842,984 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #934.
Acadian Asset Management first reported a position in PRLD in Q3 2023 and has held it in 13 quarters since. 90 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.
- Acadian Asset Management held 842,984 shares of Prelude Therapeutics worth $3.28M as of Q3 2026.
- Acadian Asset Management bought 231,625 Prelude Therapeutics shares in Q3 2026, an estimated $1.14M.
- Prelude Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2026, its #934 holding.
- Acadian Asset Management first reported a position in Prelude Therapeutics in Q3 2023 and has held it in 13 quarters since.
- 90 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.
Based on Acadian Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.